PTEN breast cancer susceptibility: a matter of dose
PTEN breast cancer susceptibility: a matter of dose
复制标题
DOI：
10.3332/ecancer.2010.192
复制
发表时间：
2010-01-01
影响因子：
1.8
通讯作者：
Alimonti, A.
中科院分区：
文献类型：
--
作者：
Alimonti, A.
The phosphatase and tensin homolog located on chromosome ten, PTEN, is one of the most commonly mutated tumor suppressor genes (TSGs) in human cancer [1-3]. PTEN catalyzes the conversion of the membrane lipid second messenger PIP3 to PIP2 and is therefore a key mediator of the AKT/PKB pathway [4,5]. Although inherited PTEN mutations predispose to the development of Cowden syndrome, which is also a breast cancer susceptibility syndrome, the role of PTEN in breast tumorigenesis has been considered minor when compared to that of other TSGs such as BRCA1 or p53 [6]. There is no current evidence that mutations in PTEN account for a substantial proportion of familial breast cancer in the absence of Cowden syndrome [6]. Moreover, PTEN mutations or deletions are not common in sporadic breast tumors, especially when compared with other tumor types (
